Investigating the function and mechanism of interleukin 7 receptor-expressing pro-angiogenic macrophages during experimental choroidal neovascularization
研究表达白细胞介素7受体的促血管生成巨噬细胞在实验性脉络膜新生血管形成过程中的功能和机制
基本信息
- 批准号:10563645
- 负责人:
- 金额:$ 40万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2028-02-29
- 项目状态:未结题
- 来源:
- 关键词:AblationAngiogenesis PathwayAnnexinsAreaAtrophicBasement membraneBlindnessBlood VesselsBone MarrowBreedingCell TherapyCellsChoroidChoroidal NeovascularizationClassificationComplementComplement ReceptorConfocal MicroscopyDataDendritic CellsDrusenEndothelial CellsExudative age-related macular degenerationEyeFibronectinsFlow CytometryFluorescence-Activated Cell SortingGenesHeterogeneityHomeostasisHumanImmuneInflammatoryInterleukin 7 ReceptorInterleukin-1 betaKnock-outLaser injuryLasersLesionLoxP-flanked alleleLymphocyteMacrophageMapsMatrix MetalloproteinasesMeasuresModelingMusOntologyOperative Surgical ProceduresPTPRC genePathogenesisPathogenicityPathologicPathway interactionsPatientsResistanceRoleSystemT-LymphocyteTamoxifenTestingTherapeuticVascular Endothelial Growth FactorsVisionWild Type Mouseangiogenesischoroidal angiogenesiscomplement pathwaycytokinediphtheria toxin receptorexperimental studyintravitreal injectionmonocytenovelnovel therapeuticsosteopontinpreventrecruitscaffoldsingle-cell RNA sequencingtargeted treatmenttranscriptome
项目摘要
PROJECT SUMMARY:
Neovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the developed world,
and is treated solely by inhibiting vascular endothelial growth factor (VEGF). Although highly effective, 15% of
patients still lose vision despite maximal anti-VEGF therapy. Thus, a critical need exists for novel non-VEGF
therapies. The complement pathway is genetically associated with AMD, macrophages express complement
proteins and receptors, and macrophages are found in surgically excised choroidal neovascularization (CNV).
Additionally, choroidal macrophage depletion results in choroidal atrophy, and both global macrophage depletion
and inhibition of classical monocyte-derived macrophages reduce experimental CNV area. Therefore,
macrophages are implicated in human CNV, steady state vascular homeostasis, and pathological choroidal
angiogenesis. However, macrophages are known to be highly heterogeneous cells that can perform many
diverse functions. Therefore, we performed single-cell RNA-sequencing on wildtype and classical monocyte-
depleted mice to investigate macrophage origin, heterogeneity, and function during laser-induced CNV. We
identified that interleukin-7 receptor (IL7R)-expressing macrophages are likely derived from classical monocytes
and display a pro-angiogenic transcriptome. Based upon these data, our central hypothesis is that IL7R+
macrophages are critical pro-angiogenic cells during CNV pathogenesis. To test this hypothesis, we formulated
the following specific aims:
1) Demonstrate that IL7R+ macrophages are necessary for CNV. In this aim, we will use Il7rCre x Rosa26GFP
mice to fate map IL7R+ macrophages, Il7rCre x Cx3cr1iDTR mice to deplete IL7R+ macrophages, and
Cx3cr1CrER x Il7rflox mice to knockout the IL7R. We will test the function of IL7R+ macrophages and the IL7R
using the laser-induced CNV model.
2) Determine that IL7R+ macrophages are derived from classical monocytes and are sufficient to stimulate CNV.
In this aim, we will use Ccr2CreER x Rosa26GFP mice to fate map classical monocytes and determine if classical
monocytes can differentiate into IL7R+ macrophages. Furthermore, we will show that IL7R+ macrophages
are sufficient to stimulate angiogenesis by isolating IL7R+ macrophages from mouse eyes after laser injury.
We will then test the ability of IL7R+ vs IL7Rneg macrophages to rescue reduced CNV area in Ccr2-/- mice.
Completion of these aims will determine that IL7R+ macrophages are necessary for CNV, derived from classical
monocytes, and sufficient to stimulate angiogenesis. These data will set the stage for cell-based anti-CNV
therapies. Cell-based therapies, targeting IL7R+ macrophages, have the potential to inhibit multiple pro-
angiogenic pathways simultaneously, rather than inhibiting VEGF alone, and change the paradigm for nAMD
therapy.
项目总结:
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeremy A Lavine其他文献
Jeremy A Lavine的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeremy A Lavine', 18)}}的其他基金
The role of beta2-adrenergic receptor and interleukin-6 signaling in macrophage-driven choroidal neovascularization
β2-肾上腺素受体和白细胞介素6信号在巨噬细胞驱动的脉络膜新生血管中的作用
- 批准号:
10334485 - 财政年份:2020
- 资助金额:
$ 40万 - 项目类别:
The role of beta2-adrenergic receptor and interleukin-6 signaling in macrophage-driven choroidal neovascularization
β2-肾上腺素受体和白细胞介素6信号在巨噬细胞驱动的脉络膜新生血管中的作用
- 批准号:
10557138 - 财政年份:2020
- 资助金额:
$ 40万 - 项目类别:














{{item.name}}会员




